Granvalor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 41.96%
(FY 2022)
- Profit 53.32%
(FY 2022)
- Ebitda 8.65%
(FY 2022)
- Net Worth 28.50%
(FY 2022)
- Total Assets 7.34%
(FY 2022)
About Granvalor Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mohammed Uddin and Khaja Aliuddin serve as directors at the Company.
- CIN/LLPIN
U24232TG2011PTC073508
- Company No.
073508
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Mar 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Granvalor Pharmaceuticals Private Limited offer?
Granvalor Pharmaceuticals Private Limited offers a wide range of products and services, including Cosmetics, Hair & Beauty Products, Face Cream, Skin Care Cosmetics, Common Disease Medicines, Pharmaceutical Medicine, Fairness Cream, Face Wash, Herbal Face Wash, Weight Gain Nutrition, Weight Gain Capsule.
Who are the key members and board of directors at Granvalor Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Uddin  | Director | 25-Mar-2011 | Current |
| Khaja Aliuddin | Director | 25-Mar-2011 | Current |
Financial Performance of Granvalor Pharmaceuticals.
Granvalor Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 41.96% increase. The company also saw a substantial improvement in profitability, with a 53.32% increase in profit. The company's net worth Soared by an impressive increase of 28.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Granvalor Pharmaceuticals?
In 2022, Granvalor Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Granvalor Pharmaceuticals?
Granvalor Pharmaceuticals has a workforce of 4 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Granvalor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Granvalor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
